Clinical Trial

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Protocol Amendment History 4 changes
notable Trial sites expanded: 13 -> 16 locations 2026-08-08
notable Trial sites expanded: 5 -> 8 locations 2026-07-03
notable Trial sites expanded: 2 -> 5 locations 2026-06-30
critical Recruitment opened 2026-06-23
Trial Details
NCT Number NCT07634471
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Follicular Lymphoma
Enrollment 960 participants
Start Date 2026-06-22
Primary Completion 2032-07-23 (estimated)
Study Completion 2035-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-14